Skip to main content
SpringerLink
Log in

Evolocumab + statin in CAD − cost effective in Japan?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Further Cardiovascular Outcome Research with PCSK9 Inhibition in Subjects with Elevated Risk

  2. Coronary Revascularization Demonstrating Outcome Study in Kyoto

Reference

  • Kodera S, et al. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. Circulation Journal : 21 Jul 2018. Available from: URL: http://doi.org/10.1253/circj.CJ-17-1455

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evolocumab + statin in CAD − cost effective in Japan?. PharmacoEcon Outcomes News 809, 19 (2018). https://doi.org/10.1007/s40274-018-5171-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5171-0

Search

Navigation